Targeting Galectin-3 Unveils the Complexity of Multiple Myeloma: A Sweet Context-Reference-Cited by-同舟云学术

Targeting Galectin-3 Unveils the Complexity of Multiple Myeloma: A Sweet Context

Published:2012-01 Issue: Volume: Page:289-307
ISSN:0097-6156
Container-title:ACS Symposium Series
language:
Short-container-title:

Author:

Mirandola Leonardo¹²³⁴,Yu Yuefei¹²³⁴,John Constance M.¹²³⁴,Jenkins Marjorie¹²³⁴,Cobos Everardo¹²³⁴,Chiriva-Internati Maurizio¹²³⁴

Affiliation:

1. Department of Health Sciences, Università degli Studi di Milano, Milano, Italy

2. Department of Internal Medicine, Pharmaceutical Sciences, Surgery, Obstetrics & Gynecology at the Division of Hematology & Oncology, School of Medicine, Texas Tech University, Health Sciences Center and Southwest Cancer Treatment and Research Center, 3601 4th St., Mail Stop 9410, Lubbock, Texas 79430, USA

3. MandalMed, 665 3rd Street, Suite 250, San Francisco, California 94107, USA

4. Laura W. Bush Institute for Women’s Health and Center for Women’s Health and Gender-Based Medicine, Amarillo, Texas 79106, USA

Publisher

American Chemical Society

Link

https://pubs.acs.org/doi/pdf/10.1021/bk-2012-1115.ch017

Reference125 articles.

1. Multiple Myeloma

2. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

3. How I treat multiple myeloma in younger patients

4. Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

5. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial